My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

20.34 -0.90 (-4.24%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

34 35 Next >

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗

November 26, 2024

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....

Via Benzinga

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

November 26, 2024

Via Benzinga

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗

November 26, 2024

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Via Investor's Business Daily

Analyst Expectations For Sarepta Therapeutics's Future ↗

November 25, 2024

Via Benzinga

Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights ↗

October 21, 2024

Via Benzinga

Unveiling 15 Analyst Insights On Sarepta Therapeutics ↗

October 21, 2024

Via Benzinga

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

November 26, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

November 25, 2024

Via Benzinga

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 07, 2024

Via Benzinga

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 07, 2024

Via Benzinga

Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics ↗

October 04, 2024

Via Benzinga

Unveiling 26 Analyst Insights On Sarepta Therapeutics ↗

September 06, 2024

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

SRPT earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

November 06, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

October 23, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 21, 2024

Via Benzinga

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

2 High-Flying Growth Stocks With Massive Upside Potential ↗

October 17, 2024

These innovative drugmakers have potential catalysts ahead.

Via The Motley Fool

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics ↗

October 03, 2024

These two could become direct competitors relatively soon.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

September 30, 2024

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy

Via MarketBeat

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

September 26, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

September 16, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

These 2 Biotech Stocks Are Set to Soar ↗

September 13, 2024

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.

Via The Motley Fool

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

September 05, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗

September 03, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.